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The p53-inducible gene PC3 (TIS21, BTG2) is endowed with antiproliferative activity. Here we report that
expression of PC3 in cycling cells induced accumulation of hypophosphorylated, growth-inhibitory forms of
pRb and led to G1 arrest. This latter was not observed in cells with genetic disruption of the Rb gene, indicating
that the PC3-mediated G1 arrest was Rb dependent. Furthermore, (i) the arrest of G1-S transition exerted by
PC3 was completely rescued by coexpression of cyclin D1 but not by that of cyclin A or E; (ii) expression of PC3
caused a significant down-regulation of cyclin D1 protein levels, also in Rb-defective cells, accompanied by
inhibition of CDK4 activity in vivo; and (iii) the removal from the PC3 molecule of residues 50 to 68, a
conserved domain of the PC3/BTG/Tob gene family, which we term GR, led to a loss of the inhibition of
proliferation as well as of the down-regulation of cyclin D1 levels. These data point to cyclin D1 down-
regulation as the main factor responsible for the growth inhibition by PC3. Such an effect was associated with
a decrease of cyclin D1 transcript and of cyclin D1 promoter activity, whereas no effect of PC3 was observed
on cyclin D1 protein stability. Taken together, these findings indicate that PC3 impairs G1-S transition by
inhibiting pRb function in consequence of a reduction of cyclin D1 levels and that PC3 acts, either directly or
indirectly, as a transcriptional regulator of cyclin D1.
The control of the cell cycle plays an essential role in cell
growth and in the activation of important cellular processes
such as differentiation and apoptosis. pRb (retinoblastoma
protein) and p53 are two molecules identified as key regulators
of the cell cycle.
pRb is a nuclear phosphoprotein whose phosphorylation
state oscillates regularly during the cell cycle. Its underphos-
phorylated forms predominate in G0 and G1, while highly
phosphorylated forms exist in S, G2, and M phases (13, 16, 21).
The primary biological function of underphosphorylated pRb
is to inhibit progression toward S phase by controlling a check-
point in late G1 (for reviews, see references 8, 22, and 51). In
fact, underphosphorylated pRb associates with members of the
E2F family of transcription factors, impairing their activity and
leading to a cell cycle block in G1. Conversely, the phosphor-
ylation of pRb inactivates its growth suppression activity by
freeing E2F molecules, thus enabling them to transactivate
genes required for the progression of the cell into S phase and
the remainder of the cell cycle (52, 97, 114).
Cyclin-dependent kinases (CDKs) are the molecules respon-
sible for pRb phosphorylation and its consequent inactivation
(reviewed in references 70 and 102). Each CDK has its own
functional specificity, based on the period of its activity during
the cell cycle and on the specific cyclin partner. CDK4, CDK5,
and CDK6 form complexes with D-type cyclins during the G1
phase (65, 69, 116). CDK2, when bound to cyclin A or E, is
instead essential for G1-to-S transition (28, 78), while the cdc2
kinase, associated with cyclins A and B, determines the G2/M
transition (78, 82, 90). Interestingly, the expression of D-type
cyclins and also their assembly with their CDK partners are
heavily dependent on stimulation by growth factors (101, 102).
If stimulation by growth factor(s) ceases, the level of D-type
cyclins decreases rapidly, their half-life being short, with a
consequent impairment of S-phase entry (7, 87). Since cells
lacking a functional Rb gene become independent from D-type
cyclins for G1/S progression, this clearly indicates that pRb is
the final target (61, 107).
A further level of control in the function of the pRb pathway
is exerted by the CDK inhibitors (reviewed in reference 103).
These are represented by two families of molecules, the INK4
family (comprising p16INK4a, p15INK4b, p18INK4c, and p19INK4c),
which causes G1 arrest by directly binding and inhibiting the
activation of CDK4 and CDK6 by D-type cyclins, and the
KIP/CIP family, which includes p27Kip1 and p21CIP1/WAF1. This
latter was identified as a potent inhibitor of all known cyclin-
CDK complexes (39, 42, 115).
Besides regulating cell cycle progression, the G1 checkpoint
function of pRb can mediate exit from the cell cycle in re-
sponse to growth-inhibitory signals or differentiation inducers.
These signals in fact activate the pRb growth suppression func-
tion by preventing its phosphorylation, thus allowing the cell to
attain the postmitotic state, an essential preliminary require-
ment for terminal differentiation of many cell types (for re-
views, see references 44 and 91). A critical role of pRb in the
control of differentiation and survival of several cell lineages,
such as neurons, lens fiber cells, cells from the cerebellar cor-
tex, and muscle and hematopoietic cells, is clearly indicated by
the phenotype of the Rb-deficient mouse (53, 54, 74, 119).
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Furthermore, pRb enhances the activities of transcription fac-
tors such as MyoD and C/EBPs in promoting muscle and
adipocyte terminal differentiation, respectively (14, 15, 38, 77).
The G1 checkpoint regulatory pathway also responds to
stressful situations and DNA damage. The p53 protein, which
is activated by different types of DNA damage, functions by
arresting the cell cycle in G1 to allow repair to take place (for
reviews, see references 4 and 56). p53 effects G1 arrest mainly
by inducing transcription of p21CIP1/WAF1, which inhibits
CDK’s activity, thus preventing pRb phosphorylation (12, 24,
27, 112, 115). Alternatively, if the growth arrest program fails,
p53 can activate an apoptotic program in the cell carrying the
DNA damage (4). Recently, the antiproliferative activity of
p53 has also been implicated in a G2/M-phase checkpoint that
controls the entry into mitosis (3).
In this context, the gene PC3, isolated by us (9) and by others
with the alternative names BTG2 (92) and TIS21 (32), plays a
role. PC3 is in fact endowed with antiproliferative activity and
is induced by p53 (72, 92). We originally isolated PC3 while
studying the onset of neuronal differentiation, induced in the
rat PC12 cell line by nerve growth factor within its first hour of
activity (9, 108). The time window chosen for our analysis of
gene induction corresponds to the period of transition between
mitosis and growth arrest that serves as a prelude to differen-
tiation (36, 37, 95). The antiproliferative properties displayed
by PC3 are consistent with such timing and are peculiar among
the immediate-early genes induced by nerve growth factor.
Furthermore, PC3 was found to be a marker for neuronal cell
birthday (47). In fact, its mRNA expression during embryonic
development of the central nervous system is restricted to the
neuroblast undergoing the last proliferation before differenti-
ating into postmitotic neuron (47). This led us to hypothesize
that PC3 is involved in the growth arrest of the neuronal
precursors (47). However, the expression of PC3 during devel-
opment and in the adult animal is not limited to the nervous
system (9, 47). Accordingly, PC3 displayed an antiproliferative
effect in different cell types, such as fibroblasts and PC12 cells
(72). Such an antiproliferative effect was afterwards confirmed
by the work of Rouault et al. (92) for the human counterpart
of the PC3 gene, i.e., BTG2. Interestingly, the same group also
showed that BTG2/PC3 is induced by p53 and that embryonic
stem cells in which BTG2/PC3 had been ablated, underwent
apoptosis following DNA damage because of failure in growth
arrest (92). These observations raise the question whether PC3
may promote p53-induced cell cycle arrest, similarly to
p21CIP1/WAF1, the prototype inhibitor of CDKs. In this regard,
it has been recently pointed out that the ability of p53 to arrest
the cell cycle in G1 is only partially dependent on the induction
of p21CIP1/WAF1 (24).
After the cloning of PC3, other novel related antiprolifera-
tive genes were isolated, namely, BTG1 (94), TOB (64), and
ANA (118). These genes share 60, 40, and 35% sequence
homology with PC3, respectively. Interestingly, the homology
of Tob to the entire BTG1 and PC3 molecules is limited to its
amino-terminal domain, whereas its carboxyl-terminal domain
interacts with the mitogenic receptor p185erbB2 (64). Since no
homology to known functional motifs is evident in the cDNA-
deduced proteins of these genes, it appears likely that PC3,
BTG1, and Tob belong to a novel functional class of cell cycle
regulators, but the question about their specific molecular
function remains open. In this regard, some suggestions came
from a recent report which showed that TIS21/BTG2 interacts
with a protein-arginine N-methyltransferase (Prmt1) by posi-
tively modulating its activity (58). Prmt1, in turn, has been
found to bind the interferon receptors and to be required for
interferon-mediated growth inhibition (2). A further interac-
tion was observed between BTG2 and the mCAF1 gene, i.e.,
the mouse homolog of the yeast CAF/POP2 gene (93). This
latter gene is part of the yeast CCR4 multisubunit complex,
which is required for the transcriptional regulation of several
genes (59, 60).
This report describes our attempts to shed light on the mo-
lecular mechanisms by which PC3 impinges on cell cycle activ-
ity. We observed that the inhibition of cell cycle progression by
PC3 requires functional pRb, and we found the existence of a
mutually exclusive interaction between PC3 and cyclin D1. In
fact, the latter blocked the PC3 effects on the cell cycle,
whereas PC3 inhibited cyclin D1 expression.
MATERIALS AND METHODS
Cell culture, cell lines, and transfections. NIH 3T3 and Rb2/2 3T3 cells and
cyclin D11/1 and cyclin D12/2 mouse embryo fibroblasts (MEFs) were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal calf
serum (HyClone, Logan, Utah) in a humidified atmosphere of 5% CO2 at 37°C.
Transfection of the plasmids was performed by the liposome technique using
the Lipofectamine reagent (Life Technologies, Gaithersburg, Md.) as per the
manufacturer’s instructions. The indicated amount of DNA (see figure legends),
diluted in Optimem containing Lipofectamine (5 or 30 ml for 35- or 90-mm-
diameter dishes, respectively), was added to the cultures, left to incubate for 5 h,
and then replaced with normal DMEM. In the experiments aimed at defining the
influence of PC3 on the phosphorylation state of pRb in NIH 3T3 cells and to
carry out cell sorting, the calcium phosphate procedure was used (34). To the cell
cultures were added the indicated amounts of DNA in calcium phosphate solu-
tion (0.5 ml for a 60-mm-diameter dish). Cells were exposed to the DNA pre-
cipitates for 20 h, washed twice with phosphate-buffered saline (PBS), and then
placed in their medium for an additional 40 h. At the end of this period, cell
cultures were used for the procedures indicated.
Plasmids, PC3 expression vectors, and mutants. The expression vector pSCT
was from B. Scha¨fer (33), who obtained it by adding an artificial polylinker to the
vector pSCT GAL 556X (96). pSCT-b-Gal was produced by inserting, in the
BamHI site of the pSCT vector, the Escherichia coli b-galactosidase (b-Gal)
gene, excised from the vector pCMVb (Clontech, Palo Alto, Calif.) as a NotI
fragment, whose ends were previously ligated to BamHI linkers. Human pRb was
expressed by the construct pCMV-pRB1, obtained by D. Livingston (85) by
inserting Rb cDNA into the pCMVneoBam vector (6). The different constructs
expressing cyclins (pRcCMV-cycA, pRcCMV-cycB1, pRcCMV-cycB2, pRcCMV-
cycD1, pRcCMV-cycD3, and pRcCMV-cycE; obtained by R. Weinberg [see
reference 45]) and CDKs (CMVcdc2, pRcCMV-CDK2, and pRcCMV-CDK4;
obtained by E. Harlow [see reference 110] and by D. Livingston [see reference
29]) were all in cytomegalovirus (CMV) promoter-driven plasmids. The expres-
sion vectors for human p16INK4a (pXp16 [99]) and mouse p27Kip1 (pCMX-p27)
were gifts of D. Beach and J. Massague`, respectively.
pSCT-PC3 was constructed by cloning into the pSCT vector the coding region
of PC3 cDNA (nucleotides 65 to 541, with the stop codon), amplified by PCR
using primers that incorporated 59 XbaI and 39 HindIII sites, and confirmed by
sequencing. The pSCT-PC3 constructs having a deletion internal to the coding
region were generated by cloning in the pSCT vector two fragments amplified by
PCR corresponding to the PC3 regions upstream and downstream of the deleted
region, joined by a PstI site in frame. The PCR primers used were as follows: (a)
mutant PC3D50–68; 59CTCGAGTCTAGAGCACCGGGCCCGCCACCATGA
GCCACGGGAAGAGA39 (PC3-PCR3, upstream sense primer containing a
flanking 59 XbaI site [underlined] and the PC3 initiator codon [underlined]),
59CGCTGCAGATGATCGGTCAGTGCGTC39 (downstream antisense primer
complementary to PC3 sequence corresponding to amino acids [aa] 44 to 49
[underlined] and flanked by a 39 PstI site), 59GGCTGCAGCGCATCAACCAC
AAGATG39 (upstream sense primer complementary to PC3 sequence corre-
sponding to aa 69 to 74 [underlined] and flanked by a 39 PstI site), and 59GGA
AGATCTATCGATAAGCTTGAATTCTCCTCTCTAGCTGGAGAC39 (PC3-
PCR4, downstream antisense primer containing a flanking 59 HindIII site
[underlined] and the PC3 termination codon [CTA in the antisense strand,
underlined]); and (b) mutant PC3D105–123; PC3-PCR3 primer, 59CGCTGCA
GGACCCACAGGGTCAGCT39 (downstream antisense primer complementary
to PC3 sequence corresponding to aa 99 to 104 [underlined] and flanked by a 39
PstI site), 59GGCTGCAGGAGGAGGCGCCGGTGGC39 (upstream sense
primer complementary to PC3 sequence corresponding to aa 124 to 129 [under-
lined] and flanked by a 39 PstI site), and a PC3-PCR4 primer. The pSCT-PC3
S147N mutant, bearing a point mutation at nucleotide 504 that mutates serine
147 to asparagine, was produced by cloning in the pSCT vector the insert
amplified by PCR with primers that incorporated 59 XbaI and 39 SalI sites:
5 9GAGTCTAGAGAATTCGCACCGGGCCCGCCACCATGAGCCACGGG
AAGAGA39 (upstream sense primer containing flanking 59 XbaI and EcoRI
sites [underlined] and the PC3 initiator codon [underlined]) and 59CGATGTC
GACCTAGCTGGAGACAGTCATCACGTAGTTCTTCGATGGATTGCTC
CT39 (downstream antisense primer containing a flanking 59 SalI site [under-
1798 GUARDAVACCARO ET AL. MOL. CELL. BIOL.
lined], the PC3 termination codon [CTA in the antisense strand, 39 to SalI site],
and the mutated nucleotide [underlined]). The corresponding construct pGEX-
PC3 S147N was obtained by restricting pSCT-PC3 S147N in SalI, blunting and
adding EcoRI linkers, and then subcloning the insert excised by EcoRI from
pSCT-PC3 S147N in frame in the EcoRI site of the pGEX-2T vector. All the
constructs obtained were checked by sequencing. The production of a protein
was verified by immunoblotting and by immunofluorescence staining with the
anti-PC3 A3H polyclonal antibody (72), by which no differences in the efficiency
of expression of the different constructs were detected.
The retroviral vector pBABE puro, a Moloney murine leukemia virus-based
vector carrying the puromycin resistance gene (75), was used for infection of cell
cultures. To obtain the pBABE puro-PC3 construct, the PC3 coding region was
subcloned into the BamHI site of pBABE puro, after amplification by PCR using
the primers 59GAGAGATCTGCACCGGGCCCGCCACCATGAGCCACGG
GAAGAGA39 as upstream sense primer (carrying a BglII site) and PC3-PCR4
as downstream antisense primer (see above). The construct was confirmed by
sequencing.
Flow cytometry assays and cell sorting. NIH 3T3 or Rb2/2 3T3 cells cotrans-
fected with pSCT-PC3 or pXp16 and with the CD20 cDNA (pCMVCD20; see
reference 122) were washed in PBS-EDTA (5 mM) and then incubated in
PBS-EDTA (5 mM) for 10 min at 37°C, harvested, and pelleted. The cell number
at the moment of harvesting was about 106 cells in a 90-mm-diameter dish. The
cell pellet was then resuspended in DMEM, centrifuged, and resuspended again
in 100 ml of DMEM containing fluorescein isothiocyanate (FITC)-conjugated
mouse monoclonal anti-CD20 antibody (Caltag Laboratories, San Francisco,
Calif.) to a final concentration of 40 mg/ml. Cells were incubated for 1 h at 4°C
and then pelleted and washed once in DMEM, to be finally resuspended in PBS.
Then, the cell suspension either was analyzed for cell cycle phase distribution
or was sorted for Western blot analysis and for reverse transcriptase PCR
(RT-PCR) analysis, using an EPICS 541 flow cytometer (Coulter Electronics,
Inc.). For cell cycle analysis, the CD20-stained cells were fixed in 70% ethanol
and stained with propidium iodide (50 mg/ml; Sigma Chemical Co.) in PBS
containing RNase A (75 kU/ml; Sigma Chemical Co.). Two-color flow cytometry
was performed, simultaneously measuring FITC (green channel) and propidium
iodide (red channel) fluorescence intensities. The total population was gated on
scatter parameters to remove cell debris. The gates to analyze cell cycle distri-
bution of CD20-PC3-expressing cells were established by measuring background
levels of FITC fluorescence, by use of vector-transfected cells incubated with a
nonspecific immunoglobulin G FITC-conjugated antibody (Caltag Laborato-
ries). DNA histograms were analyzed by a suitable mathematical model (20) to
estimate the percentage of cells in the various compartments of the cell cycle. For
Western blot analysis or for RT-PCR analysis, transfected cells were sorted on
the basis of the FITC-CD20 positivity and, immediately thereafter, lysed in
Laemmli buffer with protease inhibitors or homogenized in 4 M guanidine
thiocyanate followed by extraction with phenol-chloroform (18), respectively. An
aliquot of the Laemmli lysate was analyzed by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE), whereas an aliquot of total RNA was
used for RT-PCR analysis.
Immunofluorescence staining and antibodies. Transfected cells, grown on
polylysine-coated coverslips, were washed three times with PBS and fixed for 20
min at room temperature in PBS containing 3.75% paraformaldehyde. The
coverslips were then washed three times in PBS and incubated for 2 min in 0.1
M glycine–PBS. Permeabilization was performed with 0.1% Triton X-100 in PBS
for 6 min at room temperature. After a PBS wash, the cells were incubated for
60 min at room temperature with one primary antibody, or two where indicated,
diluted in PBS. A3H rabbit polyclonal antibody (obtained using the whole PC3
protein as immunogen and affinity purified as described in reference 72) was
diluted 1:50, anti-b-Gal rabbit polyclonal antibody (Chemicon International,
Inc., Temecula, Calif.) was diluted 1:50, and antibromodeoxyuridine (BrdU)
mouse monoclonal antibody (Amersham, Little Chalfont, England) was used
undiluted, whereas affinity-purified rabbit polyclonal antibodies anti-cyclin A
(C19; Santa Cruz Biotechnology, Heidelberg, Germany) and anti-cyclin E (M-20;
Santa Cruz Biotechnology), as well as anti-cyclin D1 mouse monoclonal antibody
72-13G specific for rodent cyclin D1 (Santa Cruz Biotechnology; see reference
66), were used at a final concentration of 2 mg/ml. After three washes in PBS, the
cells were incubated for 30 min at room temperature with the secondary anti-
body(ies), either FITC conjugated (Myles-Yeda, Rehovot, Israel) or TRITC
(tetramethylrhodamine isothiocyanate) conjugated (Sigma Chemicals), and then
washed three times with PBS. Cells were finally mounted with PBS-glycerol (3:1).
The immunofluorescence assay was performed on a Leitz Dialux 22 microscope.
DNA synthesis assays were performed by adding 50 mM BrdU to the culture
medium 24 to 18 h before fixation. To detect BrdU, DNA denaturation was
obtained by adding 50 mM NaOH for 10 s after permeabilization with 0.1%
Triton X-100 and was followed by three PBS washes. BrdU was detected by
undiluted anti-BrdU monoclonal antibody (Amersham RPN 202) added to-
gether with the other primary antibody as described above, followed by FITC-
conjugated goat antibody to mouse immunoglobulin G (Sigma F9006). To detect
nuclei, cells were incubated at the end of the immunofluorescence staining
procedure for 2 min in Hoechst 33258 dye diluted in PBS at 1 mg/ml (Sigma),
washed twice in PBS, and mounted as described above.
Immunoblotting analysis and antibodies. Transfected cell cultures (after cell
sorting where indicated) were lysed into Laemmli buffer (125 mM Tris-HCl [pH
6.8], 10% glycerol, 2.1% SDS) containing 0.5 M b-mercaptoethanol, 1 mM
phenylmethylsulfonyl fluoride (PMSF), 10 mg of leupeptin per ml, and 10 mg of
aprotinin per ml and heated for 5 min at 100°C. An aliquot was analyzed by
SDS–10% PAGE. After electrophoresis, proteins were electrophoretically trans-
ferred to nitrocellulose (12 to 16 h at 65 mA in 24 mM Tris-HCl [pH 8.3]–166
mM glycine–20% methanol). The filters were then soaked for 2 h in blocking
buffer (TBS [10 mM Tris HCl (pH 8), 150 mM NaCl]–0.05% Tween–5% pow-
dered milk) and then incubated in the same buffer for 2 h with the first antibody.
This latter was one of the following: the anti-PC3 affinity-purified rabbit poly-
clonal A3H antibody (diluted 1:1,000); the affinity-purified rabbit polyclonal
antibody anti-cyclin A (sc-596), anti-cyclin E (sc-481), anti-cdc2 (sc-53), anti-
CDK2 (sc-163), or anti-CDK4 (sc-260); the mouse monoclonal antibody anti-
cyclin D1 72-13G specific for rodent cyclin D1 (all from Santa Cruz Biotechnol-
ogy, diluted 1:200); and the mouse monoclonal antibody anti-b-actin (clone
AC-15, diluted 1:5,000; Sigma Chemical). After three washes in TBS with 0.05%
FIG. 1. Induction of pRb dephosphorylation by PC3 and its reversal by
cyclins. (A) Ectopic expression of PC3 leads to dephosphorylation of pRb. NIH
3T3 cells (1.3 3 105) were seeded onto 60-mm-diameter dishes. After 24 h, cells
were transfected with the human Rb expression plasmid pCMVpRb (4.5 mg)
together with the pSCT (VEC), pSCT-PC3 (PC3), or pRSVRasAsn17 (Ras N17)
expression vector (4.5 mg each), as indicated. Control cells without transfected
plasmids were also analyzed (NT). After 60 h, cells were lysed in Laemmli buffer
and pRb was detected by Western blotting using the G3-245 monoclonal anti-
body. (B) Reversal by cyclins of the PC3-mediated pRb dephosphorylation. NIH
3T3 cells (1.3 3 105) were seeded onto 60-mm-diameter dishes. After 24 h, cells
were transfected with pCMVpRb (4.5 mg) together with expression vectors for
PC3, cyclins, or cyclin-dependent kinases (4.5 mg each), as indicated. In trans-
fections where Rb or PC3 expression constructs were absent, a corresponding
amount of the empty vectors (4.5 mg of each) was used. Equal amounts of cell
lysates were analyzed for pRb and PC3 expression by immunoblotting. Protein
loading was verified by b-actin detection.
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Tween, the filter was incubated in blocking buffer containing the second antibody
(either goat anti-rabbit or goat anti-mouse horseradish peroxidase-conjugated
antibody; Pierce, Rockford, Ill.). After three washes in TBS with 0.05% Tween,
detection of the second antibody was performed by chemiluminescent assay.
Anti-pRb immunoblotting was performed with the G3-245 monoclonal antibody
(Pharmingen, San Diego, Calif.; diluted to a final concentration of 1 mg/ml) used
as described above, with the only differences being that SDS-PAGE had 7%
polyacrylamide and blocking buffer contained 0.4% gelatin in place of powdered
milk. The intensity of the bands of the immunoblots was quantified by an EPA
3000 densitometer (Sanwatsusho, Tokyo, Japan) in the linear range of the film.
The intensity values of the sample were normalized to the corresponding values
of b-actin.
RNA extraction and RT-PCR assay. Total cellular RNA was obtained from
sorted cells according to the procedure of Chomczynski and Sacchi (18) (see
above) and was analyzed by semiquantitative RT-PCR as previously described
(72). Four micrograms of total RNA was treated with DNase (RQ1; Promega; 2
U) and then denatured at 75°C for 5 min and added to a total reaction volume
of 50 ml containing 13 RT buffer (10 mM Tris-HCl [pH 8.8], 50 mM KCl, 0.1%
Triton X-100), 5 mM MgCl2, 0.5 mM (each) deoxynucleoside triphosphate, 1 U
of RNasin (Promega), and 600 pmol of random hexamer primers. Moloney
murine leukemia virus RT (200 U; Promega) was added to one-half reaction
volume (25 ml) and incubated for 2 h at 37°C (the remaining reaction volume
without RT was kept to be used as a control in PCR amplifications for possible
contamination of the sample with genomic DNA). RT reaction mixtures were
stored at 220°C and then used for PCR amplification. Two microliters of each
RT reaction mixture was amplified in a 100-ml PCR mixture containing 13 PCR
buffer (10 mM Tris-HCl [pH 9] at 25°C, 50 mM KCl, 0.1% Triton X-100), 0.2
mM (each) deoxynucleoside triphosphate, 1.5 mM MgCl2, 20 pmol of each
primer (see below), and 2 U of Taq polymerase (Promega). The number of cycles
was designed so as to maintain the reactions of amplification in exponential
phase (20 cycles for b-actin and 35 cycles for all the other templates). Coampli-
fication of b-actin mRNA gave a measure of the efficiency of the reaction and of
the starting RNA amount in each sample, since b-actin is constitutively expressed
in the cell lines used. Amplification profiles were the following: denaturation at
95°C for 5 min during the first cycle or at 94°C for 1 min in the remaining cycles,
primer annealing at 50°C (for b-actin, cyclin A, and PC3; at 52°C for cyclins D1
and E) for 1 min, and primer extension at 72°C for 1.5 min. About 1/10 of the
PCR sample was electrophoresed on a 1.2% agarose gel, blotted onto a nylon
filter, and hybridized to 32P-labeled specific oligonucleotides (whose sequence
was internal to the region amplified by PCR): (a) cyclin A (59-CAGAGTGTG
AAGATGCCCTGG-39), (b) cyclin D1 (59-CCATGCTCAAGACGGAGGAG
A-39), (c) cyclin E (59-GGCGAGGATGAGAGCAGTTCT-39), (d) PC3 (59-CC
GTAGGTTTCCTCACCAGTC-39), and (e) b-actin (59-CAGCTGAGAGGGA
AATCGTGC-39). The relative product amounts were quantitated by analysis
with a Molecular Dynamics 400A PhosphorImager system. The PCR primers
used were as follows: (a) cyclin A, 59 (59-TGCTCCTCTTAAGGACCTT-39) and
39 (59-TCAGAACCTGCTTCTTGGA-39); (b) cyclin D1, 59 (59-ACACCAATC
TCCTCAACGA-39) and 39 (59-TAGCAGGAGAGGAAGTTGT-39); (c) cyclin
E, 59 (59-GAAAATCAGACCACCCAGA-39) and 39 (59-ATACAAAGCAGAA
GCAGCG-39); (d) PC3, 59 (59-ATGAGCCACGGGAAGAGA-39) and 39 (59-C
CTGAAGTTC TCAGCTCT-39) (this latter primer is reverse complementary to
the pSCT polylinker in the region 39 of the cloning site of PC3, and thus the
PC3-amplified product derives only from the PC3 exogenous transcript); and (e)
b-actin, 59 (59-TTGAGACCTTCAACACCC-39) and 39 (59-GCAGCTCATAG
CTCTTCT-39). All the oligonucleotides except those for PC3 were from mouse
cDNA sequences.
Reporter gene assay. NIH 3T3 cell cultures were transfected with the indicated
PC3 or E2F-1 expression constructs. The variations in the amounts of expression
vectors were completely compensated for by addition of the corresponding
empty DNA plasmid vectors. Transfection of the expression construct cDNAs
was performed in parallel with the positive-control simian virus 40 promoter-
driven pGL2 control plasmid (Promega). Luciferase activity of each sample (Li)
was corrected for differences in transfection by normalization, measuring the
amount of plasmid DNA present in each extract of the transfected cells (Di), as
determined by dot blot hybridization according to a previously described proce-
dure (1). Plasmid DNA was visualized using as a probe a 3-kb BamHI-SmaI
fragment from the noncoding region of vector pGL2, to avoid possible interac-
tions with RNA. The formula used was luciferase activity normalized 5 Li 3
Dm/Di, where Dm is the average value for each experiment. The fold activity was
then obtained by dividing each normalized value of luciferase activity by the
average number of normalized luciferase units of the corresponding control
culture.
Metabolic labeling and immunoprecipitation. NIH 3T3 cultures transfected
with Flag-tagged cyclin D1 construct (kindly provided by C. Sherr [26]) were
washed twice in DMEM without methionine, preincubated in the same medium
for an hour, and then labeled by incubation in methionine-free DMEM contain-
ing Pro-mix35S (0.15 mCi of [35S]methionine per ml) for 2 h. Afterwards, cultures
were washed twice in DMEM with an excess of cold methionine, incubated in the
same medium for the indicated time periods, and lysed by 30 min of incubation
at 4°C in ice-cold lysis buffer (50 mM Tris-HCl [pH 7.5], 1 mM EDTA, and 150
mM NaCl, containing 1% Triton X-100, 5 mg of leupeptin per ml, 5 mg of
aprotinin per ml, and 1 mM PMSF). After clearing by centrifugation at 10,000 3
g for 15 min, extracts were assayed for protein concentration (10); 500-mg
aliquots were then precleared using a rabbit preimmune serum and protein
G-Sepharose (Amersham Pharmacia Biotech) for 1 h at 4°C. After centrifuga-
tion at 12,000 3 g, the supernatants were incubated with protein G-Sepharose
with the anti-Flag M2 mouse monoclonal antibody (Sigma; F3165; 3 mg per
sample) for 2 h at 4°C. The immunocomplexes were washed three times in lysis
buffer and then resuspended in Laemmli buffer containing protease inhibitors,
heat denatured, and run on SDS-polyacrylamide gels.
Production and purification of GST fusion proteins. The vector pGEX-2T-
PC3 was obtained by subcloning in frame into pGEX-2T the coding region of
PC3, excised as a 59 BamHI-39 EcoRI PCR-amplified fragment from the vector
pRSETA-PC3, in which it had been previously cloned. The restriction reaction
for the site BamHI was partial, given the existence of a BamHI site internal to
PC3. The construct was checked by sequence analysis. Human pGEX-p21 and
pGEX-p16 were from Y. Xiong. pGEX-PC3 S147N was obtained as described
above. The fusion proteins, after lysis of the bacterial pellet in PBS with 0.5%
NP-40, were purified through glutathione S-transferase (GST)–Sepharose beads
(Pharmacia) and eluted per the manufacturer’s instructions. The proteins were
stored at 280°C until use, either bound to GST-Sepharose beads (for in vitro
binding assays) or in elution buffer (for in vitro kinase assays; 30 mM reduced
glutathione, 60 mM HEPES [pH 7.5], 30 mg of leupeptin per ml, 1 mM PMSF)
at a concentration of about 0.3 mg/ml at 280°C until use.
In vitro binding assays. Expression and purification of GST fusion pro-
teins were performed as described above. Mouse pCMV-cdc2 (110), human
pRcCMV-CDK2 and pRcCMV-CDK4 (29), and human pBSK-glob-CDK6 (68)
were transcribed and translated in vitro using 35 ml of nuclease-treated rabbit
reticulocyte lysate (Promega) as described elsewhere (41). The programmed
lysates (1.5 ml) were incubated with GST, GST-PC3, GST-p16, or GST-p21
beads (20 ml, carrying about 15 mg of bound protein) for 2 h at 4°C. The beads
were washed five times with 20 volumes of NET-N buffer (20 mM Tris-HCl [pH
FIG. 2. Rb-dependent inhibition of S-phase entry by PC3. (A to L) Representative immunofluorescence photomicrographs of BrdU incorporation in NIH 3T3 (A
to F) and Rb2/2 (G to L) cells transfected with PC3. NIH 3T3 and Rb2/2 3T3 cells (0.8 3 105) were seeded onto coverslips in 35-mm-diameter dishes. After 24 h,
cells were transfected with the expression vector pSCT-b-Gal or pSCT-PC3 (1.5 mg each). DNA synthesis assays were performed by adding 50 mM BrdU to the culture
medium 40 h after transfection. After 18 to 20 h, cells were fixed, permeabilized, and stained. b-Gal and PC3 proteins were revealed using anti-b-Gal (A and G) or
anti-PC3 (i.e., A3H [D and J]) polyclonal antibodies followed by incubation with goat anti-rabbit TRITC-conjugated antibody. BrdU was visualized by anti-BrdU
monoclonal antibody (corresponding photomicrographs C, F, I, and L) followed by goat anti-mouse FITC-conjugated antibody. Nuclei were detected by Hoechst 33258
dye (corresponding photomicrographs B, E, H, and K). Arrows indicate the positions of nuclei that did not incorporate BrdU. Bar, 30 mm. (M) Percentage of
BrdU-incorporating cells (NIH 3T3 or Rb2/2 3T3, as indicated) after transfection with pSCT-PC3 (filled bars) or control pSCT-b-Gal (open bars). Values are
calculated as the percentages of cells positive for BrdU, detected between cells positive for b-Gal and those positive for PC3, whose total number within each experiment
was assumed to be 100%. Means 6 SEM are from three independent experiments (a representative field is shown in A to L). The number of cells counted for each
group is indicated at the top of each bar. p, P 5 0.0000 versus any other group (Student’s t test). (N) Flow cytometry analysis of PC3 (filled bars) or p16 (open bars)
effects on cell cycle profile in NIH 3T3 and Rb2/2 3T3 cells. NIH 3T3 or Rb2/2 3T3 cells (3 3 105) were seeded onto 90-mm-diameter culture dishes; after 24 h, cells
were transfected either with the pSCT empty plasmid (8.5 mg), with pSCT-PC3 (8.5 mg), or with pXp16 plasmid (8.5 mg), together with a plasmid encoding the CD20
cell surface marker (pCMVCD20, 3 mg). After 60 h, transfected cells were identified by staining with an FITC-conjugated anti-CD20 antibody, and their cell cycle
distribution was measured by analyzing the DNA content after staining with propidium iodide, using two-color flow cytometry. Data from three independent
experiments are shown as means 6 SEM of the changes in the percentages of cells in G0/G1 or S cycle phase, compared to the corresponding value of the control
transfection with the empty vector pSCT. (O) Effects of PC3 on cell cycle profile of Rb2/2 3T3 cells upon readdition of Rb. Rb2/2 3T3 cells were transfected with
pCMVpRb (0.5 mg) or its empty vector. To each of these two treatments was added either pSCT-PC3 (7.5 mg, filled bars) or the pSCT empty plasmid (7.5 mg, open
bars). The plasmid encoding the CD20 cell surface marker (pCMVCD20, 3 mg) was used in all transfections. Shown are the changes in the percentages of cells in G0/G1
or S cycle phase induced by addition of pRb (compared for each group to the corresponding value of the control transfection in the absence of pRb), with or without
PC3 as indicated. Data are means 6 SEM from three independent experiments.
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8], 100 mM NaCl, 1 mM EDTA, 0.5% Nonidet P-40, 0.5% nonfat dry milk
containing 10 mg of leupeptin per ml, 1 mM PMSF) and then mixed with 1
volume of 23 SDS loading buffer. Bound proteins were analyzed by SDS-PAGE.
Production of cyclins and CDKs in insect cells. Baculoviruses expressing
His-tagged cyclin A, His-tagged cyclin B1, hemagglutinin-tagged cdc2, and hem-
agglutinin-tagged CDK2 were provided by D. Morgan (25), while cyclin D1 and
CDK4 were provided by C. Sherr (49). In the preparation of insect lysates
(essentially as described in reference 115), 2.5 3 106 Sf9 cells were infected with
the indicated cyclin and/or CDK viruses at a multiplicity of infection of 10. After
40 h, cells were lysed in 0.4 ml of kinase buffer (see below) by five passages
through a 26-gauge needle and used for kinase assays. The cell lysates were then
cleared of insoluble material by two centrifugations at 10,000 3 g and stored at
280°C or directly used for kinase assays.
Retroviral infections. High-titered retroviral supernatants (about 1 3 106 to
5 3 106 virus/ml) were generated by transient transfection with calcium phos-
phate of either pBABE puro vector as a control or pBABE puro-PC3, in the
helper-free packaging cell line BOSC23, according to a procedure described
elsewhere (80). The supernatants were then used to infect NIH 3T3 cells ac-
cording to a protocol described elsewhere (111). Briefly, cell cultures (4 3 105
cells for each 90-mm-diameter dish) were infected for 5 h and then replated and
exposed for 48 h to puromycin (2 mg/ml). This procedure allowed us to obtain a
pure culture of cells expressing the retroviral constructs, given that all nonin-
fected cells detached from the plate. The cultures at the moment of harvesting
were subconfluent. Cells were divided into aliquots, either in lysis buffer for
kinase assays (used immediately; see below) and Western blotting or in PBS for
cell cycle profile analysis (used after fixation).
Kinase assays. Kinase assays were performed basically as described by Toyo-
shima and Hunter (109). For the assays of CDK activities in vitro using the
baculovirus system, to the lysate of Sf9 cells (in kinase buffer: 50 mM HEPES
[pH 7.4], 10 mM MgCl2, 2.5 mM EGTA, 1 mM dithiothreitol [DTT], 10 mM
b-glycerophosphate, 0.1 mM Na3VO4, 1 mM NaF, 1 mM PMSF, 10 mg of
leupeptin per ml, 5 mg of aprotinin per ml) coinfected with CDKs and cyclins (2
to 16 ml) was added either GST-PC3, GST-p21, or GST-p16 (5 to 1,600 ng, as
indicated), and the mixtures were incubated at 30°C for 20 min. Reactions were
started by adding 250 ng of GST-Rb (769–921) fusion protein (Santa Cruz
Biotechnology) as substrate, 25 mM ATP, and 5 mCi of [g-32P]ATP (6,000
Ci/mmol; Amersham), and reaction mixtures were incubated for 10 min at 30°C.
Differences in the volumes of baculovirus lysates were compensated for by
addition of wild-type baculovirus lysate, in order to attain a final reaction volume
of 20 ml. Reactions were then terminated by adding 200 ml of stop buffer (50 mM
Tris HCl [pH 8.0], 150 mM NaCl, 20 mM EDTA, 1 mM EGTA, 10% glycerol),
also containing glutathione-Sepharose beads (Pharmacia) in order to recover
GST-pRb, and incubating the mixture for 1 h at 4°C. The GST-Rb protein bound
to glutathione-Sepharose beads was then washed twice in stop buffer, eluted by
addition of sample buffer, and analyzed by SDS–10% PAGE. 32P-labeled pro-
teins were detected by autoradiography. For analysis of the phosphorylation of
PC3 by cyclin A-CDK2, the substrates used were either 800 ng of GST-PC3
S147N, GST-PC3, or GST or 250 ng of GST-Rb.
For the assays of CDK activities in vivo on retrovirus-transduced NIH 3T3
cells, infected cultures were lysed by resuspension in lysis buffer (50 mM HEPES
[pH 7.5], 200 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 0.1% Tween
20, 10% glycerol, 0.1 mM sodium orthovanadate, 1 mM NaF, 1 mM PMSF, 10
mg of leupeptin per ml, 5 mg of aprotinin per ml, 10 mM b-glycerophosphate) for
30 min at 4°C, followed by four cycles of 5 s of sonication at low power and
clearing by centrifugation at 14,000 rpm for 5 min at 4°C. Supernatants were
assayed for protein concentration as described elsewhere (10). Protein samples
of 0.5 mg (CDK2 assay) or 2 mg (CDK4 assay) were then precleared with rabbit
immunoglobulin G and then immunoprecipitated for 2 to 4 h at 4°C with protein
A-Sepharose beads (Amersham Pharmacia Biotech) precoated with saturating
amounts of the appropriate antibody (5 mg of either sc-163 or sc-260, respec-
tively; anti-CDK2 or anti-CDK4 from Santa Cruz; 1 h of preincubation at 4°C).
Immunoprecipitated proteins on beads were washed twice with 1 ml of lysis
buffer and twice with 1 ml of wash buffer (50 mM HEPES [pH 7.5], 1 mM DTT,
10 mM MgCl2, plus the protease inhibitors as described above). The beads were
resuspended in 50 ml of kinase buffer (see above) containing 2 mg of GST-pRb
(769–921) fusion protein (Santa Cruz Biotechnology, Inc.), 20 mM ATP, and 10
mCi of [g-32P]ATP (NEN Dupont, Boston, Mass.; 6,000 Ci/mmol). After incu-
bation for 30 min at 30°C, the samples were boiled in 23 Laemmli buffer,
separated by SDS-PAGE, and transferred to a nitrocellulose filter. Phosphory-
lated proteins were visualized and quantitated by densitometry using a Molecular
Dynamics 400A PhosphorImager system.
Colony formation assay. The colony formation assay was used to measure the
growth inhibition by the PC3 mutants and was performed on NIH 3T3 cells
according to the procedure previously described (72). NIH 3T3 cells (2.3 3 105)
were plated into 60-mm-diameter dishes and after 24 h transfected by the
Lipofectamine procedure with pSCT-PC3 (3.8 mg), either wild type or mutated,
or with the empty vector pSCT (3.8 mg), together with the vector carrying the
neomycin resistance gene (pcDNA3; 0.5 mg). After 48 h, two aliquots of each
culture were split into 90-mm-diameter dishes (2 3 105 and 1 3 105 cells) and
grown in medium containing G418 (0.5 mg/ml), to allow resistant cells to form
colonies. A third aliquot (6 3 105 cells) was lysed and used for Western blotting,
to measure the expression of the PC3 construct used. The cutoff point for colony
size was .20 cells/colony. Percentages of growth inhibition were calculated with
the formula pi 5 ci 3 100/vi, where ci is the number of colonies in the dish
transfected in experiment (i) with the indicated mutant, and vi is the number of
colonies in the dish transfected in the same experiment (i) with the empty vector.
Statistical analysis was performed on the original raw number of colonies, com-
paring the ci with the vi values of all the experiments by Student’s t test.
RESULTS
PC3 overexpression leads to pRb hypophosphorylation. We
have previously shown that PC3, when overexpressed, inhibits
proliferation, leading to an impairment of the G1/S transition,
concomitantly with dephosphorylation of pRb (72). Since the
growth-inhibitory activity of pRb is regulated by phosphoryla-
tion (13, 16), these findings suggested that PC3 exerts its an-
tiproliferative activity by preventing pRb phosphorylation.
Given that our observations were for NIH 3T3 cell clones
stably expressing exogenous PC3, in which secondary muta-
tional events might have occurred during the selection procedure,
we sought to evaluate the effect of PC3 on pRb phosphoryla-
tion in transiently transfected cells. Therefore, asynchronously
growing NIH 3T3 mouse fibroblasts, which do not express
detectable levels of endogenous PC3 (72), were cotransfected
with expression vectors for pRb and PC3. As a positive control,
the pRb expression construct was alternatively cotransfected
with the dominant interfering Ras mutant RasAsn17 (Fig. 1A).
This mutant induces disruption of Ras function, resulting in G1
cell cycle arrest and pRb dephosphorylation (30, 81). Trans-
fected cells were harvested 60 h posttransfection, and cell ly-
sates were analyzed for pRb expression and phosphorylation
state by Western blotting. We observed that the ectopic ex-
pression of pRb alone was detected as a single band of 115,000
in Mr, corresponding to the hyperphosphorylated (inactive)
form (13, 16), while coexpression of pRb with PC3 led to the
appearance also of the 105,000-Mr band, corresponding to the
hypophosphorylated (active) form of pRb (Fig. 1A). In the
presence of RasAsn17, pRb was almost totally detected as a
105,000-Mr singlet.
The phosphorylation state of pRb depends on the activity of
the cyclin-CDK complexes, whose activity, in turn, depends on
the cyclin levels (50, 66). Therefore, we sought to assess if the
effects of PC3 seen on pRb phosphorylation could be influ-
enced by coexpression of cyclins (Fig. 1B). We observed that
all the cyclins tested, namely, cyclins D1, E, and A, led to
almost complete disappearance of the hypophosphorylated
form of pRb elicited by PC3 (Fig. 1B). In contrast, CDK4 and
CDK2 alone did not counteract the effect of PC3 on pRb
dephosphorylation (Fig. 1B). These results strongly suggest
that the PC3-dependent appearance of the hypophosphory-
lated, active form of pRb could be responsible for the cell cycle
impairment by PC3.
PC3 arrests G1/S progression depending on the presence of
Rb. If the mechanism by which PC3 inhibits cell growth is by
counteracting pRb phosphorylation, then its ability to induce
cell cycle arrest would be lost in cells lacking functional pRb.
To ascertain this possibility, we examined the effect of PC3 on
cell cycle progression, specifically from the G1 to the S phase,
in NIH 3T3 compared to Rb2/2 3T3 cells. These latter cells
lack the gene for Rb but remain responsive to signals that
restrain proliferation independently from Rb (81). The two cell
lines were transiently transfected with PC3 or, alternatively,
with a b-Gal expression construct as a negative control, and the
DNA synthesis was determined by means of BrdU incorpora-
tion. The PC3- or the b-Gal-expressing cells were identified by
immunofluorescence staining, either with the anti-PC3 affinity-
purified polyclonal antibody A3H (72) or with an anti-b-Gal
rabbit polyclonal antibody, while the cells that entered into S
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phase were identified by staining with an anti-BrdU antibody
(Fig. 2A to L, showing a representative experiment). We ob-
served that expression of PC3 led to inhibition of BrdU incor-
poration in NIH 3T3 cells (Fig. 2D to F), compared to control
cultures (Fig. 2A to C). Such inhibition was significant, as
clearly indicated by the frequency values for BrdU incorpora-
tion (Fig. 2M). In contrast, no significant effect was produced
by PC3 on BrdU incorporation in Rb2/2 3T3 cells (Fig. 2J to
M). The same result was seen in primary Rb1/1 and Rb2/2
MEFs, transiently transfected with PC3 (data not shown).
These results indicate that PC3 arrests the progression toward
the S phase in an Rb-dependent manner.
As a further analysis of this point, we sought to measure the
cell cycle profile of NIH 3T3 and Rb2/2 3T3 cells expressing
ectopic PC3. To this end, we cotransfected the pSCT-PC3
expression construct with the cell surface marker CD20 (105)
cloned into an expression vector (122) and analyzed the cell
cycle profile of transfected cells by means of two-color flow
cytometry (Fig. 2N). The expression of PC3 in NIH 3T3 cells
induced a significant percent increase of the cell population in
the G1 phase, accompanied by a complementary decrease of
the S phase, while no significant effect was seen in the PC3-
expressing Rb2/2 3T3 cells (Fig. 2N, filled bars). No evident
changes were observed in the G2/M-phase cell population
(data not shown). Furthermore, ectopic expression of the pRb-
dependent CDK inhibitor p16INK4a gave the same effects on
the cell cycle profile as seen with PC3, i.e., a significant in-
crease of G0/G1 and decrease of S phase only in NIH 3T3 cells
(Fig. 2N, open bars). Thus, PC3, similar to p16INK4a, caused an
Rb-dependent impairment of G1-S transition. Our Rb
2/2 3T3
cell clone was, however, fully responsive to the CDK inhibitor
p27Kip1, transfected as expression vector pCMX-p27 ([26.2 6
0.53]% increase of cells in G0/G1 phase and [216.8 6 2.97]%
decrease of cells in S phase, expressed as changes in percent-
age 6 standard errors of the mean [SEM]). Given that p27Kip1
acts through a pRb-independent pathway (81), this confirmed
that the clone did not undergo mutational changes in the
course of our experimentation, remaining responsive to Rb-
FIG. 3. Expression of cyclin D1 rescues the PC3-dependent G1 arrest. NIH 3T3 cells (0.8 3 105) were seeded onto 35-mm-diameter dishes. After 24 h, cells were
transfected with the expression vector pSCT-PC3 (PC3, 0.4 mg, filled bars) or pSCT-b-Gal (GAL, 0.4 mg, open bars), together with the indicated cyclins (0.8 mg) and
CDKs (0.8 mg). In transfections where the CDK or the cyclin was absent, a corresponding amount (0.8 mg) of the empty CMV vector was cotransfected. Detection of
transfected cells expressing PC3 or b-Gal and analysis of their DNA synthesis by measuring BrdU incorporation were performed as described in the Fig. 2A legend.
At least 90 cells were scored for each experiment. The results are means 6 SEM of at least three independent experiments. ppp, P 5 0.0000 versus GAL; pp, P , 0.0001
versus GAL; p, P , 0.001 versus GAL; N.S., P . 0.05 versus GAL (Student’s t test).
FIG. 4. Inhibition of cyclin D1 expression by PC3 in NIH 3T3 and Rb2/2
cells. NIH 3T3 and Rb2/2 3T3 cells (3 3 105) were seeded onto 90-mm-diameter
culture dishes. After 24 h, cells were transfected with either pSCT empty plasmid
(VEC; 21 mg for each dish, total of seven dishes for each cell line) or pSCT-PC3
(21 mg for each dish, total of seven dishes for each cell line), together with a
plasmid encoding the CD20 cell surface marker (pCMVCD20, 3 mg). Sixty hours
after, extracts from transfected cells isolated by CD20-specific cell sorting were
subjected to immunoblotting with antibodies specific for the cyclin and CDK
proteins indicated.
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FIG. 5. Inhibition of cyclin D1 nuclear immunofluorescence staining by ectopic PC3 in NIH 3T3 and Rb2/2 cells. (A to L) Representative immunofluorescence
photomicrographs of cyclin D1 expression in NIH 3T3 (A to F) and Rb2/2 3T3 (G to L) cells transfected with PC3 (or control b-Gal). NIH 3T3 or Rb2/2 3T3 cells
(0.8 3 105) were seeded onto coverslips in 35-mm-diameter dishes and transfected with the expression vector pSCT-b-Gal or pSCT-PC3 (1.5 mg each). After 60 h, cells
were fixed, permeabilized, and stained. b-Gal and PC3 proteins were detected with anti-b-Gal (A and G) or anti-PC3 (D and J) polyclonal antibodies, followed by goat
anti-rabbit TRITC-conjugated antibody. Nuclei were stained by Hoechst 33258 dye (corresponding photomicrographs B, H, E, and K). Cyclin D1 was visualized by
anti-cyclin D1 mouse monoclonal antibody, followed by goat anti-mouse FITC-conjugated antibody (corresponding photomicrographs C, I, F, and L). Arrows indicate
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independent stimuli. We also checked whether in Rb2/2 3T3
cells the inhibitory effect of PC3 on G1-S progression could be
reinstated after reintroduction of pRb by transfection (Fig.
2O). In fact, the percent changes in the cell populations in G1
or S phases induced by PC3 cotransfected with exogenous pRb
(filled bars, Fig. 2O) attained about the same level seen in NIH
3T3 cells transfected with PC3 alone, if the basal effect of
exogenous pRb is subtracted (open bars, Fig. 2O).
Cyclin D1 expression reverses the PC3-induced cell cycle
block. As a whole, the above results indicate that PC3 impairs
G1-to-S-phase progression by means of an active pRb, also
given the ability of cyclin-CDKs to reverse the PC3-induced
dephosphorylation of pRb (Fig. 1B).
To further elucidate this aspect of the mechanism by which
PC3 blocks cell cycle progression, we examined whether over-
expression of cyclins could overcome the inhibitory effect of
PC3 on G1/S progression. To this aim, NIH 3T3 cells were
transiently transfected with PC3 in either the presence or the
absence of cyclins and CDKs, and the entry of cells into S
phase was monitored by means of BrdU incorporation (Fig. 3).
While cyclins A, D3, E, B1, and B2 only partially counteracted
the impairment of DNA synthesis elicited by PC3 (with an
increase of BrdU incorporation ranging from 16 up to 25 to
40% of the basal level), cyclin D1 led to a significant (80%)
recovery of the basal level (86% when cyclin D1 was coex-
pressed with CDK4). These data point to cyclin D1 as an
essential component in the pathway(s) responsible for the PC3
inhibitory activity on the cell cycle. Generally, coexpression of
CDKs with cyclins and PC3 led to a recovery of BrdU incor-
poration that was very similar to that brought about by cyclins
alone. This is consistent with the previous observation that
CDK2 and CDK4 alone did not modify the PC3-dependent
hypophosphorylation of pRb (Fig. 1B).
The ectopic expression of PC3 down-regulates cyclin D1
levels. The observation that cyclin D1 was able to rescue the
cell-growth-inhibitory effect of PC3, taken together with the
well-established requirement for cyclin D1 in G1 progression
(7), suggested that the cell cycle block imposed by PC3 could
be consequent to a reduction of cyclin D1 levels.
Thus, we wished to evaluate the effects of ectopic PC3 on the
endogenous levels of cyclins and CDKs, by immunoblotting.
Given that the cells which took up and expressed the tran-
siently transfected PC3 were not more than 10 to 20% in our
experimental conditions, to improve the detection of protein
levels the population of cells successfully transfected was en-
riched up to 90% by flow cytometry, using the cotransfected
CD20 antigen as a marker protein. It turned out that cyclin D1
indeed was reduced by PC3 expression, in both NIH 3T3 and
Rb2/2 3T3 cells (Fig. 4), about threefold, as judged by densi-
tometry scanning. The other cyclins and CDKs analyzed did
not show significant changes in their levels, except for a slight
reduction of cyclin E in Rb2/2 3T3 cells. As expected, the
levels of the different cyclins in control transfections were
similar for both NIH 3T3 and Rb2/2 3T3 cells (43, 61).
As an independent assessment, we verified by immunofluo-
rescence staining the expression of cyclin D1 and cyclin A in
cells transfected with pSCT-PC3 or with the control vector
pSCT-b-Gal (Fig. 5A to L). Cells expressing ectopic PC3 were
detected by using the anti-PC3 antibody A3H (72). Again, it
was observed that in both NIH 3T3 and Rb2/2 3T3 cells
expressing ectopic PC3 the cyclin D1 nuclear immunostaining
was detectable at a frequency significantly lower (fivefold) than
that in cells expressing ectopic b-Gal (Fig. 5A to L and M,
showing the frequency values for cyclin D1 nuclear staining).
On the other hand, cyclin A expression in both NIH 3T3 and
Rb2/2 3T3 cells transfected with PC3 remained the same as in
control cultures transfected with b-Gal (Fig. 5N).
PC3 down-regulates the transcription of the cyclin D1 gene.
The above findings raised the question whether the reduction
of cyclin D1 protein levels elicited by PC3 was a consequence
of down-regulation of cyclin D1 transcription. To this aim, we
analyzed the cyclin D1, A, and E mRNA levels in PC3-express-
ing cells by semiquantitative RT-PCR. Cells expressing exog-
enous PC3 were enriched as previously indicated by selecting
the cell population expressing the CD20 marker cotransfected
with PC3. We observed that cyclin D1 mRNA levels were
significantly reduced by PC3, about 2.5- and 3-fold, compared
to the levels of NIH 3T3 and Rb2/2 3T3 control cells, respec-
tively (Fig. 6A and B). The mRNA levels of cyclin E appeared
to be not significantly decreased in NIH 3T3 cells and to be
slightly increased by PC3 in Rb2/2 3T3 cells (1.4-fold),
whereas those of cyclin A were not significantly increased in
both cell types (1.2-fold [Fig. 6A and B]). Thus, to assess the
existence of transcriptional regulation by PC3, we analyzed the
effect of PC3 on the activity of the cloned cyclin D1 promoter,
transiently transfected into NIH 3T3 cells. We used the con-
struct prCD1-1810, which contains 1,810 nucleotides 59 to the
transcription start in front of the luciferase reporter gene in the
vector pGL2 (see reference 117). The activity of the cyclin D1
promoter in cells cotransfected with PC3 was compared to that
of cells cotransfected with the empty vector. As a control of the
efficiency of transfection, we measured the amount of plasmid
DNA present in each cell extract by dot blot hybridization,
according to a previously described procedure (1). We ob-
served that PC3 reduced the activity of cyclin D1 promoter up
to threefold, with a concentration-dependent effect (Fig. 6C).
A similar effect on the cyclin D1 promoter was also observed
for E2F-1, known to inhibit the cyclin D1 promoter (113), used
as an internal experimental control.
A further analysis was performed to verify whether PC3, in
addition to its effects on cyclin D1 transcription, could also
affect the stability of cyclin D1 protein. To this aim, we mea-
sured the half-life of Flag-tagged cyclin D1, cotransfected in
NIH 3T3 cells with either pSCT-PC3 or pSCT control vector.
Cells were metabolically labeled with [35S]methionine, and the
lysates were immunoprecipitated with an antibody to Flag (Fig.
7A). We observed that PC3 did not produce significant differ-
ences in the turnover kinetics of Flag-tagged cyclin D1 protein,
given its half-life of 23.3 6 5 and 21.5 6 4 min in the absence
and the presence of PC3, respectively (average values 6 SEM
the positions of nuclei negative for cyclin D1 staining. Bar, 40 mm. (M) Percentage of NIH 3T3 and Rb2/2 3T3 cells positive for cyclin D1 immunofluorescence staining
after transfection with pSCT-b-Gal (open bars) or pSCT-PC3 (filled bars). Values are calculated as the percentages of cells positive for cyclin D1 nuclear staining,
detected between cells positive for b-Gal and those positive for PC3, whose total number within each experiment was assumed to be 100%. Means 6 SEM of three
independent experiments, performed as described above for panels A to L, which are a representative field, are shown. p, P 5 0.0000 versus the corresponding control
(Student’s t test). The number of cells counted for each group is indicated at the top of each bar. (N) Percentage of cyclin A-positive cells by immunofluorescence
staining after transfection with pSCT-b-Gal (open bars) or pSCT-PC3 (filled bars). Transfection and detection of PC3 and b-Gal were performed as described for panels
A to L. However, in order to distinguish the reactivity to the rabbit polyclonal anti-cyclin A antibody from that to either anti-PC3 (A3H) or anti-b-Gal (all rabbit
polyclonal antibodies), cells were incubated first with anti-cyclin A and then with a mouse anti-rabbit antibody, washed, and fixed. Incubation with A3H (or anti-b-Gal)
followed. Anti-cyclin A and anti-PC3 (or anti-b-Gal) antibodies were detected by goat anti-mouse FITC-conjugated and goat anti-rabbit TRITC-conjugated antibodies,
respectively. Values are the means 6 SEM of three independent experiments. The number of cells counted for each group is indicated at the top of each bar.
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obtained by linear regression analysis of the data of four inde-
pendent experiments, shown in Fig. 7B).
Cell cycle blocking activity of PC3 mutants. A comparison of
the protein sequences of the PC3/BTG/Tob gene family shows
the existence of conserved regions with higher homology. By
comparing, through the algorithm Align, the protein sequences
of rat PC3 (72), human PC3 (whose cDNA, isolated by us with
EMBL accession no. Y09943, corresponds to BTG2 [see ref-
erence 92]), Tob (64), and BTG1 (94), we identified two con-
served regions that correspond, in the PC3 protein, to residues
50 to 68 and 105 to 123 (Fig. 8A). We reasoned that such
regions, given the common ability of these genes to inhibit
proliferation, might play a role in that effect. To analyze this
possibility, we produced two PC3 mutants with an internal
deletion, comprising either residues 50 to 68 or 105 to 123
(pSCT-PC3 D50–68 and pSCT-PC3 D105–123, respectively).
Furthermore, the PC3 protein contains a sequence motif
known as the consensus site for phosphorylation by cdc2
and/or CDK2 (46). Therefore, we produced a third mutant,
pSCT-PC3 S147N, whose serine 147, which belongs to the
phosphorylation motif mentioned, was replaced with aspara-
gine (Fig. 8A). We found that cyclin A-CDK2, expressed in
baculovirus, was able to phosphorylate the wild-type PC3 mol-
ecule but did not phosphorylate the mutant pSCT-PC3 S147N
(Fig. 9), indicating that indeed PC3 is phosphorylated by cyclin
A-CDK2 at the consensus aa 147 (while PC3 did not appear to
be a substrate either of cyclin B1-cdc2 or of cyclin D1-CDK4
[data not shown]).
FIG. 6. Inhibition of cyclin D1 transcription by PC3. (A) Inhibition of cyclin D1 mRNA levels in NIH 3T3 and Rb2/2 3T3 cells by PC3. Cells (3 3 105) were seeded
onto 90-mm-diameter culture dishes and transfected with either pSCT empty plasmid or pSCT-PC3 (21 mg each) together with a plasmid encoding the CD20 cell surface
marker (pCMVCD20, 3 mg), as described for Fig. 4. Sixty hours after, cells were isolated by CD20-specific cell sorting (obtaining 3 3 105 to 5 3 105 cells), and total
RNA was extracted. The specific mRNA species indicated were visualized by RT-PCR analysis using specific primers. Equal amounts of RT-PCR products amplified
from NIH 3T3 or Rb2/2 3T3 sorted cells, transfected with either pSCT-PC3 or the empty vector, were electrophoresed, blotted on a filter, and hybridized to probes
for cyclins A, E, and D1; PC3; and b-actin. RT “1” or “2” indicates the products of amplification performed in parallel on two aliquots of each RNA starting sample
preincubated or not with RT, respectively, in order to check the presence of DNA contamination. Control amplifications using as template the cDNA corresponding
to each mRNA species gave a signal of the expected size (data not shown). (B) Relative levels of the mRNAs, as means 6 SEM of three independent experiments,
of which a representative one is shown in panel A. Values were obtained by measuring Southern blot densities of the PCR product of each experiment with a
PhosphorImager system and were represented as ratios of the density observed in pC3-transfected cells to the corresponding one in pCST-transfected cells (assumed
to be 1; see control bars). Values were then corrected for the corresponding b-actin relative expression, according to the following formula: relative sample density 5
sample density in PC3-transfected cells 3 100/sample density in vector-transfected cells/(b-actin density in PC3-transfected cells 3 100/b-actin density in vector-
transfected cells). Black bars, NIH 3T3 cells; grey bars, Rb2/2 3T3 cells. (C) Inhibitory effect of PC3 on cyclin D1 promoter activity. NIH 3T3 cells (105) seeded onto
35-mm-diameter culture dishes were transfected after 24 h with either pSCT-PC3 or CMV–E2F-1 or the corresponding empty plasmids. Forty-eight hours after
transfections, cell lysates were collected and assayed for luciferase activity. The fold decrease in luciferase activity was calculated relative to the level of control samples
(transfected with the empty vectors), which were set to the unit. The bars represent the average fold activities 6 SEM of three independent experiments performed
in duplicate. The luciferase activities were measured in luciferase units per microgram of protein normalized to the amount of plasmid DNA present in each extract
(black or grey bars). The ratio of transfected expression vector to reporter plasmid is shown on the abscissa. The amount of reporter used was 0.5 mg, while the highest
amount of pSCT-PC3 and CMV–E2F-1 was 1.5 mg (corresponding to a molar ratio of expression vector to reporter of 4.5 and 3.0, respectively).
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The ability of the PC3 mutants to inhibit cell proliferation
was then analyzed by colony formation assay. This revealed
that growth inhibition was lost for the D50–68 mutant, which
even presented a slight paradoxical stimulatory effect, whereas
for the D105–123 mutant the ability to inhibit growth, although
still significant, was severely reduced. The mutation of aa 147
led only to a slight impairment of the growth inhibition of PC3
(Fig. 8B). In parallel with the colony formation assays, the
expression of the PC3 mutated proteins was analyzed by West-
ern blotting and was shown to be equivalent to that of the
wild-type PC3, indicating that the effects on growth were not
due to differences in the expression of the PC3 mutants (Fig.
8C and statistical analysis of the expression in Fig. 8D). The
intracellular localization of the mutated PC3 proteins did not
differ from that of wild-type PC3, being apparently cytoplas-
mic, as judged from immunostaining with the antibody A3H
(Fig. 8E).
We have previously observed that ectopic expression of PC3
concomitantly induces down-regulation of cyclin D1 levels and
G1 arrest, suggesting that these two events are correlated. To
verify this possibility, we checked the ability of the PC3 mu-
tants analyzed for their effects on growth to affect cyclin D1
levels. To this aim, the expression of cyclin D1 was assessed by
immunofluorescence staining in cells transfected either with
pSCT-PC3, pSCT-PC3 D50–68, pSCT-PC3 D105–123, or
pSCT-PC3 S147N or with the control vector pSCT-b-Gal (Fig.
8F). It was shown that the mutants negatively affected the
frequency of cyclin D1 expression in the following order of
potency: PC3 wild type . PC3 S147N . PC3 D105–123 . PC3
D50–68 (Fig. 8F).
As a whole, these data suggested the existence of a correla-
tion between the inhibition of proliferation and the reduction
of cyclin D1 expression elicited by PC3.
Exclusivity of the cyclin D1 pathway for PC3. A further
question raised by these findings, pointing to a negative regu-
latory control of cyclin D1 levels exerted by PC3 in correlation
with inhibition of G1-S progression, concerned the exclusivity
of such control, in regard to the possible involvement of other
cell cycle pathways different from cyclin D1. To this aim, we
verified the ability of PC3 to inhibit S-phase progression in
primary MEF cells explanted from an animal ablated of the
cyclin D1 gene, by measuring BrdU incorporation. Cyclin
D11/1 and cyclin D12/2 MEF cells, transiently transfected
with the PC3 or the control b-Gal expression constructs, were
identified for their expression by immunofluorescence staining
with the anti-PC3 or anti-b-Gal polyclonal antibodies and
monitored for BrdU incorporation by double labeling with the
BrdU monoclonal antibody (Fig. 10). We observed that expres-
sion of PC3 led to inhibition of BrdU incorporation in both cell
types, although to different extents, i.e., about 45% inhibition
in cyclin D11/1 cells and 23% inhibition in cyclin D12/2 cells,
compared to control cultures, being statistically significant only
in the former cell type (Fig. 10).
PC3 indirectly inhibits CDK2 and CDK4 activity. The
strong impairment of cyclin D1 levels by PC3 can by itself fully
account for the pRb-dependent cell cycle arrest induced by
PC3, given that phosphorylation of pRb by cyclin D1-CDK4
complexes is the prerequisite for G1 progression (for reviews,
see references 70, 101, and 102). We wished to verify this point
by analyzing the effect of PC3 on the activity in vivo of CDK4,
and CDK2 as well, in NIH 3T3 cells. The generation of a large
population of pure PC3-expressing cells, necessary for the ki-
nase assays, was obtained by expressing PC3 through retroviral
infection. The retroviral vector pBABE puro, in which the
complete coding region of PC3 cDNA was cloned, was used to
generate the high-titered retroviral supernatants employed to
infect NIH 3T3 cultures, according to a procedure described
elsewhere (80). These cultures offered an additional system in
which to verify our previous findings. In fact, in the course of
our analyses we observed that cell cultures infected with the
PC3 retrovirus presented a high expression of PC3 concomi-
tant with a reduced expression of cyclin D1 protein and
mRNA, accompanied by an increase of the cell population in
G1 phase and a decrease of cells in S phase (Fig. 11A and data
not shown), as already seen in PC3-expressing cells sorted by
flow cytometry from transiently transfected cultures. In cul-
tures infected with the PC3 retrovirus, we then observed a
decrease, with respect to the control group, of both CDK4- and
CDK2-mediated Rb kinase activities, the effect on CDK2 be-
ing less evident but well reproducible (Fig. 11B).
A further analysis that we performed concerned the possi-
bility of a direct inhibition of CDK activities by PC3. This
latter, implying a cell cycle arrest by PC3 occurring also inde-
pendently from its effect on cyclin D1 transcription, was con-
sidered on account of the interaction seen between PC3 and
CDKs, by means of a GST pull-down analysis using in vitro-
translated CDKs. In fact, we found that, while p21CIP1/WAF1
and p16INK4a showed the expected associations with cdc2 and
FIG. 7. The half-life of Flag-tagged cyclin D1 protein is not changed by PC3.
(A) Forty-five hours after cotransfection of NIH 3T3 cultures (2.3 3 105 cells in
60-mm-diameter dishes) with Flag-tagged cyclin D1 (2.15 mg) and either pSCT-
b-Gal or pSCT-PC3 (2.15 mg each), cells were metabolically labeled for 2 h with
[35S]methionine. Cells were washed with medium containing an excess of unla-
beled methionine, collected, and lysed at the indicated times. Cell lysates con-
taining equal amounts of proteins were then immunoprecipitated using the M2
monoclonal antibody against the Flag epitope. A control transfected with pSCT
vector without Flag-tagged cyclin D1 is shown in lane 1. Shown are results of a
representative experiment. (B) Graphic representation of Flag-tagged cyclin D1
expression. The data at individual time points are the amounts of 35S-labeled
Flag-tagged cyclin D1 protein as measured by a PhosphorImager system and are
the means 6 SEM of four independent experiments. The half-lives of Flag-
tagged cyclin D1 protein were calculated for each experiment by linear regres-
sion analysis of the density values at the different time points, transformed by
common logarithm.
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CDK2 (Fig. 12A and B) (see also references 42 and 121) and
with CDK4 and CDK6 (Fig. 12C and D) (see also references
40 and 116), respectively, PC3 was shown to be associated with
cdc2 to an extent higher than that of p21CIP1/WAF1 (Fig. 12A) and
also, although weakly, with CDK4 (Fig. 12C). Thereafter, we
tested whether PC3 could inhibit the pRb kinasing activity of
different cyclins-CDKs expressed in Sf9 insect cells, using a
GST-Rb fusion protein as substrate. Purified GST-PC3 was
compared either to purified GST-p21CIP1/WAF1, for the ability
to inhibit cyclin B1-cdc2 and cyclin A-CDK2, or to purified
GST-p16, for the ability to inhibit cyclin D1-CDK4 (Fig. 13).
Purified GST was used as negative control. This choice was in
agreement with the observation that p21CIP1/WAF1, although able
to inhibit the activity of several CDKs (115), is, however, a
more efficient inhibitor of cyclin B-cdc2 and cyclin A- and
E-CDK2 activities than of cyclin D-CDK4 (42, 121), while
p16INK4a preferentially inhibits CDK4 and CDK6 (86, 99). It
turned out that while p21CIP1/WAF1 and p16INK4a dose depen-
dently inhibited the corresponding cyclins-CDKs, PC3 did not
show significant effects (Fig. 13). Therefore, under the condi-
tions used, we can rule out a direct inhibitory effect of PC3 on
the activity of the CDKs analyzed.
DISCUSSION
We show in this report that the gene PC3 inhibits S-phase
entry in an Rb-dependent manner and that this effect is cor-
related with its ability to inhibit cyclin D1 expression.
The PC3-mediated arrest of G1/S progression is Rb depen-
dent. PC3 induces an evident inhibition of cell cycle progres-
sion from G1 to S phase, as judged by the severe impairment of
DNA synthesis observed in cycling cells expressing ectopic
PC3. Accordingly, flow cytometry analysis of cell cultures
transfected with PC3 shows that the population of cells in S
phase undergoes a significant decrease, while that of cells in G1
shows a parallel increase. The impairment of G1/S transition by
PC3 observed in this report confirms and extends our previous
observations made with clones stably expressing PC3 (72). Fur-
thermore, our analyses of Rb2/2 cells indicate that the inhibi-
tion of S-phase entry by PC3 requires the presence of pRb, the
key molecule responsible for growth arrest and accumulation
of cells in G1 in response to antiproliferative signals (for re-
views, see references 44 and 114). In fact, in Rb2/2 cells PC3
fails to arrest DNA synthesis, as seen by BrdU incorporation,
and to alter the population of cells in S phase, according to the
cell cycle profile analysis by flow cytometry. Such findings agree
with our observation that the PC3-dependent block of S-phase
entry is rescued by coexpression of cyclin D1, whose activity is
necessary for G1-to-S progression in an Rb-dependent manner
(61, 107).
It is worthwhile to point out that the impairment of G1/S
transition is an effect shared by PC3 with another p53-induced
gene, p21CIP1/WAF1. Earlier observations indicated that, fol-
lowing DNA damage, MEFs lacking p21CIP1/WAF1 show a par-
tial defect in G1 arrest that is less severe than that of p53-
defective fibroblasts, thus making plausible the idea that other
p53-dependent G1 arrest pathways exist (24).
Additionally, it has been observed that the G2 arrest that
occurs following DNA damage is not detected in embryonic
stem cells ablated of PC3/BTG2, thus suggesting that PC3
might also be implicated in the p53-mediated G2 arrest (92).
However, it was observed that PC3/BTG22/2 cells presented a
marked increase in cell death, and it was not possible to define
if the loss of G2/M arrest resulted from the absence of a
specific G2 block, ongoing apoptosis, or loss of other factors
(92). Nonetheless, a possibility to be considered is that PC3
could inhibit cell cycle progression also at checkpoints different
from G1/S, by other, additional Rb-dependent or Rb-indepen-
dent pathways.
Correlation between down-regulation of cyclin D1 levels and
cell cycle impairment by PC3. The inhibition of the G1-S tran-
sition by PC3 is accompanied by down-regulation of cyclin D1
levels. Given the necessity of cyclin D1 for G1 progression (7,
87, 107), the cyclin D1 decrease effected by PC3 might in itself
FIG. 9. Phosphorylation of PC3 at aa 147 by cyclin A-CDK2. Lysates of Sf9
cells coinfected with either CDK2 and cyclin A or wild-type baculovirus lysates
were assayed in 20-ml reaction mixtures for GST-PC3 S147N, GST-PC3, GST, or
GST-Rb phosphorylation by measuring incorporation of 32P. Samples were an-
alyzed by SDS-PAGE. Shown is the autoradiograph from the area of the gel
containing the substrate proteins. W.T., wild type.
FIG. 8. Effects of the ectopic expression of wild-type and mutant PC3 constructs on cell growth arrest and cyclin D1 expression. (A) Schematic representation of
PC3 mutants; the hatched boxes inside the PC3 sequence represent the regions conserved among the different members of the PC3 family. (B, C, and D) NIH 3T3
cells were transfected with the indicated pSCT-PC3 construct (either wild type or mutant; 3.8 mg) or with the empty vector pSCT (3.8 mg). The vector carrying the
neomycin resistance gene (pcDNA3, 0.5 mg) was included in each transfection. The transfected cultures were then split into three fractions 48 h after transfection, two
for the colony formation assay (2 3 105 and 1 3 105 cells [B]) and a second (6 3 105 cells) for protein expression analysis by Western blotting (C and D). (B) For the
colony formation assay, the colonies resistant to G418 after 2 weeks of selection, arising from each transfected construct, were counted and expressed as percentages
of the number of resistant colonies formed by transfection of the empty vector. Calculations are means 6 SEM from four independent experiments. VEC,
vector-cotransfected cells, considered 100% of colony formation. p, P , 0.05 versus VEC control group (Student’s t test); pp, P , 0.01 versus VEC control group
(Student’s t test). (C and D) Equal amounts of cell lysates were used for Western blot analysis; (C) representative experiment analyzing the PC3 and b-actin protein
levels; (D) means 6 SEM of protein expression levels as judged by densitometry analysis of the four independent experiments, after normalization to the corresponding
b-actin expression level (unity 5 the expression of PC3 wild-type protein for each experiment). (E) Immunofluorescence photomicrographs showing NIH 3T3 cells
expressing either wild-type or mutated PC3, as indicated. Detection was done by the anti-PC3 antibody. The lower panels show nuclear staining, using Hoechst 33258
dye. Bar, 25 mm. (F) Percentage of NIH 3T3 cells positive for cyclin D1 immunofluorescence staining after transfection with pSCT-b-Gal, pSCT-PC3, pSCT-PC3
D50–68, pSCT-PC3 D105–123, or pSCT-S147N mutants (1.5 mg each). Transfections, as well as detection of proteins (PC3 [wild type and mutated], b-Gal, and cyclin
D1), were performed as described for Fig. 5A to L. Values are the means 6 SEM of four independent experiments. p, P , 0.05 versus b-Gal control group (Student’s
t test); N.S., P . 0.05 versus b-Gal control group (Student’s t test). The number of cells counted for each group is indicated at the top of each bar. w.t. and W.T., wild
type.
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be sufficient to explain the PC3-induced cell cycle arrest. In
fact, the formation of an active cyclin D1-CDK4 complex de-
pends on de novo synthesis of D1 protein (66). Furthermore,
the impairment in the ability of PC3 to lower cyclin D1 levels,
seen in consequence of mutations of the PC3 molecule, corre-
lates with the extent of impairment in growth arrest. This
indicates that inhibition of proliferation and down-regulation
of cyclin D1 levels by PC3 are events significantly connected.
Remarkably, the fact that PC3 significantly inhibits cyclin D1
expression also in cells lacking pRb indicates that such an
effect is genuinely dependent on PC3 and is not secondary to
other effects consequent to the Rb-dependent cell cycle arrest
in G1. In second place, it follows that the signaling pathway
between PC3 and cyclin D1 in Rb2/2 3T3 cells is intact.
Conversely, cyclin D1 is able to rescue the PC3-dependent
G1 arrest, evidence pointing to cyclin D1 as a target for the
PC3 inhibition of the cell cycle. Furthermore, the ability of PC3
to impair cyclin D1 expression, as well as the ability of cyclin
D1 to reverse the cell cycle block by PC3, appears to be pref-
erential, since the level of cyclin A is unaffected by PC3, while
that of cyclin E is only slightly reduced in 3T3 Rb2/2 cells, and
the G1 arrest elicited by PC3 is not reversed by these cyclins.
As a whole, this indicates a significant functional correlation
between PC3 and cyclin D1, which can be placed upstream of
pRb. Given that pRb is the sole critical substrate of CDKs
regulated by D-type cyclins, this makes somewhat selective the
functional correlation between PC3 and, downstream, pRb.
Nonetheless, it should be considered that the rescue per-
formed by cyclin D1 of the PC3-dependent impairment in
S-phase entry did not attain 100% and, more important, that
the inhibition by PC3 of G1-S progression is detectable, even
though only partially, in cyclin D12/2 MEF cells also. These
points, in our view, suggest that the cyclin D1 pathway, al-
though preferential for the PC3-dependent effect on G1-S pro-
gression, is not exclusive.
Many pieces of evidence point to the existence of a homeo-
static network regulating pRb activity, centered on cyclin D1.
Synthesis and accumulation of cyclin D1, triggered by growth
factors or by molecules activated along their pathways, e.g., ras
(31, 71, 81), lead to inactivation of pRb by CDK4-dependent
FIG. 10. Assessment of the inhibition of G1-S progression by PC3 in cyclin
D12/2 cells. About 0.8 3 105 cyclin D11/1 and cyclin D12/2 MEF cells were
seeded onto coverslips in 35-mm-diameter dishes and transfected after 24 h with
the expression vector pSCT-b-Gal or pSCT-PC3 (1.5 mg each). DNA synthesis
assays were performed by adding 50 mM BrdU to the culture medium 36 h after
transfection. After 24 h, cells were fixed, permeabilized, and stained. b-Gal and
PC3 proteins were revealed with the polyclonal antibodies anti-b-Gal and anti-
PC3, respectively, followed by goat anti-rabbit TRITC-conjugated antibody,
whereas BrdU was visualized by anti-BrdU monoclonal antibody followed by
goat anti-mouse FITC-conjugated antibody, as described for Fig. 2. The percent-
ages of BrdU-incorporating cells shown are means 6 SEM of three independent
experiments. The number of cells counted for each group is indicated at the top
of each bar. p, P , 0.001 versus control group (Student’s t test).
FIG. 11. Effect of PC3 on the protein kinase activities of cyclins-CDKs in
vivo. (A) Characterization by Western blotting of NIH 3T3 cultures infected with
retrovirus carrying the PC3 coding region or with empty vector (from superna-
tants of BOSC23 cells transfected with the pBABE puro-PC3 or pBABE puro
vector, respectively). Equal amounts of proteins were loaded. (B) In vivo activity
of CDK2 and CDK4 in NIH 3T3 cells infected with the PC3 retrovirus or with
the empty retrovirus, as indicated. Equal amounts of proteins, from NIH 3T3
lysates of cultures infected with PC3 retrovirus or empty retrovirus, were immu-
noprecipitated with normal rabbit serum (NRS) or with anti-CDK2 and anti-
CDK4 antibodies and then assayed for GST-Rb phosphorylation in 50-ml reac-
tion mixtures by measuring incorporation of 32P. Samples were loaded in SDS-
PAGE gels and transferred by electrophoresis to a nitrocellulose filter. This was
analyzed for the presence of phosphorylated GST-Rb by a PhosphorImager
(upper panels). The immunoprecipitated samples were checked for the presence
of equal amounts of CDK2 and CDK4 proteins by Western blot analysis of the
nitrocellulose filter (lower panels). INF., infected; I.P., immunoprecipitation.
FIG. 12. In vitro interactions of PC3 with CDKs. Shown is binding of GST,
GST-PC3, and GST-p21 or GST-p16 to cdc2 (A), CDK2 (B), CDK4 (C), or
CDK6 (D). Equal amounts of [35S]methionine-labeled CDKs (shown in the left
lanes of each panel) were incubated with GST-PC3, GST-p21, or GST-p16, as
indicated. Bound proteins were eluted and analyzed by SDS-PAGE (6% poly-
acrylamide for cdc2, 9% polyacrylamide for CDK2 and CDK6, and 12% poly-
acrylamide for CDK4) and autoradiography. Numbers at left of each panel are
molecular masses in kilodaltons.
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phosphorylation (for reviews, see references 101 and 114) and
thus to the release of molecules that trigger the cell cycle, such
as E2F-1 (52, 97). At the end of G1/S transition, a down-
regulation of cyclin D1 levels follows, in consequence of at
least two events triggered by pRb inactivation, i.e., an increase
of free E2F-1 molecules, which leads to repression of cyclin D1
transcription (113), and the increase of p16INK4a, which leads
to displacement of cyclin D1 from CDK4 and to its degrada-
tion (106). Thus, phosphorylated, inactive pRb exerts negative
control on cyclin D1 levels. These remain low until pRb is
made active again at the end of mitosis by dephosphorylation.
Then, active pRb leads to accumulation of cyclin D1 (76) and,
consequently, to CDK4-dependent phosphorylation of pRb,
with a negative feedback loop on its activity. Thus, the down-
regulation by PC3 of cyclin D1 expression should not only
negatively influence cyclin D1-CDK4 activity but also have
other effects predictable from the context mentioned above
(e.g., on p16INK4a or E2F levels).
Regarding the mechanisms by which PC3 down-regulates
cyclin D1 levels, our data clearly show that PC3 negatively
influences cyclin D1 transcription and does not affect the sta-
bility of cyclin D1 protein. In fact, the decreases of the levels of
cyclin D1 transcript and protein caused by PC3 were quanti-
tatively similar, and they were also accompanied by inhibition
of cyclin D1 promoter activity, indicating that PC3 can repress
cyclin D1 gene transcription, which accounts for the decrease
of cyclin D1 protein. Thus, our data suggest that PC3 acts,
either directly or indirectly, as a transcriptional regulator. This
idea is in agreement with the recent observation that PC3/
BTG2 binds the mouse homolog of the yeast protein yCAF1
(93). This gene, together with the yeast cell-cycle-regulated
protein kinase DBF2, the NOT proteins, and other yet-uni-
dentified proteins, is part of the yeast transcriptional regula-
tory complex CCR4, which plays an important general tran-
scriptional role in diverse cellular processes (59, 60). It is
interesting that mutations of yeast CCR4, CAF1, and DBF2
lead to a delayed exit from late mitosis (60) and that mutations
of yCAF1 are able to suppress defects in DNA repair (98).
The observations of the subcellular localization of PC3 (as
determined by immunofluorescence staining of transfected
cells, in this report and in reference 72) clearly show its pres-
ence in the cytoplasm but also leave open the possibility of a
nuclear localization. In the latter case, the participation of PC3
in a transcriptional complex could occur also in the nucleus.
Our data also show that PC3 can associate with CDK4 in
vitro. However, assuming that this observation can be repro-
duced in vivo, it appears unlikely that the binding of PC3 to
CDK4 might displace the cyclin D1 protein, thus inducing its
degradation (as for instance seen with p16INK4a [106]), since
PC3 was unable to directly inhibit pRb phosphorylation by
cyclin D1-CDK4 and to influence cyclin D1 protein stability.
Rather, we see that PC3 behaves as an indirect CDK inhibitor,
as judged from the detection of reduced activity of CDK4 and
CDK2 in PC3-expressing cells. While the inhibition of CDK4
may well be consequent to the PC3-dependent reduction of
cyclin D1 levels, the effect on CDK2 is less obvious, given that
no evident effect of PC3 on the levels of cyclins E and A,
cofactors of CDK2, was seen for NIH 3T3 cells. However, it
has been shown that the activity of CDK2 can be inhibited by
a decrease of cyclin D1-CDK4 complexes. In fact, a reduction
of cyclin D1 would lead to a lower fraction of cyclin D1-CDK4
complexes available to bind the CDK inhibitor p27 and con-
sequently to a larger number of active p27 molecules able to
inhibit CDK2 activity (89).
Recently, a report appeared showing that exogenous TIS21/
PC3, stably expressed in the tumor 293 cell line, induced G1
arrest accompanied by a decrease of cyclin E protein levels and
CDK2 activity (57). It is worth noting that these cells lack
cyclin D1 and have both nonfunctional pRb and nonfunctional
p53, due to the expression of adenovirus type 5 E1A and E1B
transforming proteins, respectively (35, 73). In this regard,
previous reports suggested that in systems with inactive pRb,
such as tumor cells, S-phase progression can be regulated by
cyclin E in place of cyclin D (55) and that cyclin E expression
can overcome a pRb-dependent block of the cell cycle (5, 62),
thus suggesting that cyclin E might induce cell cycle progres-
sion through pathways independent from and downstream of
pRb. Importantly, we observed that in 3T3 Rb2/2 cells PC3 led
to a decrease also of cyclin E protein, although considerably
less pronounced than that of cyclin D1 (Fig. 4). Given that we
found cyclin E to be ineffective in rescuing the inhibition of G1
progression by PC3 in NIH 3T3 cells carrying an active pRb
gene and that in our cell system the cycle arrest induced by PC3
depended biunivocally on the presence of pRb, a hypothesis
that might account for our data and for those of Lim et al. (57)
is that PC3 induces the arrest of the cell cycle through at least
two pathways, involving cyclin D1 and cyclin E. The latter
could become evident when there is impairment of pRb func-
tion and, possibly, of other cell cycle regulators such as, for
instance, p53. Further analyses will certainly be necessary for a
thorough understanding of this point.
PC3-dependent hypophosphorylation of pRb and its rever-
sal by cyclins. The PC3-dependent dephosphorylation of pRb
FIG. 13. Effect of PC3 on the in vitro protein kinase activities of cyclin
B1-cdc2, cyclin A-CDK2, and cyclin D1-CDK4. Lysates of Sf9 cells containing
the indicated combination of cyclin-CDK and in the presence of increasing
amounts (in nanograms) of GST-p21, GST-p16, GST-PC3, or GST were assayed
in 20-ml reaction mixtures for GST-Rb phosphorylation by measuring incorpo-
ration of 32P. Samples were analyzed by SDS-PAGE. Shown is the autoradio-
graph from the area of the gel containing the GST-Rb protein. cdc2, CDK2, and
CDK4 denote lysates from Sf9 cells infected with the CDK baculovirus alone as
a control.
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in NIH 3T3 cells is a clear indication that PC3 influences the
activity of pRb.
However, PC3 does not lead to complete disappearance of
the phosphorylated pRb forms. This fact should be the result
of concomitant phosphorylation of pRb by CDKs different
from CDK4, whose regulatory cyclins are not down-regulated
by PC3. This possibility is suggested by the observation that not
only cyclin D1 but also cyclins E and A prevent the PC3-
dependent impairment of pRb phosphorylation. Noteworthily,
this fact is in apparent contrast to the quite exclusive functional
correlation seen between PC3 and cyclin D1, i.e., the rescue by
cyclin D1 of the G1/S impairment exerted by PC3 and the
PC3-dependent down-regulation of cyclin D1 levels. In fact,
the position of the pRb residue undergoing phosphorylation is
more critical, in terms of impairment of pRb’s antiproliferative
activity, than the total number of phosphorylated residues. In
particular, for a complete inactivation of pRb by CDK2 and
cdc2 in S phase, a preliminary phosphorylation in G1/S by
CDK4 is required (19, 63, 88). Thus, the complete conversion
by cyclins A and E (and their associated CDK2 and cdc2
kinases) of the PC3-dependent dephosphorylated form of pRb
into a phosphorylated one, seen in a denaturing gel, should
result in a pRb still active in growth arrest. In agreement,
cyclins A and E led to a nonsignificant rescue of the PC3-
dependent inhibition of proliferation. All together, these data
indicate that the final target of PC3 is pRb.
Functional domains of PC3. Colony formation assay data for
PC3 mutants point to a functional role in cell proliferation for
the region corresponding to aa 50 to 68 (which we term here
GR, for growth regulatory), namely, the more amino terminal
of the two conserved regions existing within the PC3/BTG/Tob
family. In fact, deletion of GR (mutant PC3D50–68) led to a
complete impairment of the growth-inhibitory properties of
PC3 and to almost complete loss of the ability to inhibit cyclin
D1. On the other hand, deletion of the conserved domain
spanning aa 105 to 123 partially reduced the inhibitory effect
on growth and on cyclin D1 expression by PC3. Therefore, it is
possible that the GR domain plays a direct role in conferring
on the PC3 molecule its antiproliferative properties. Alterna-
tive and not mutually exclusive hypotheses are that the GR
motif has a role ancillary to that of other domains and that it
requires the cooperation of other regions of the molecule, as
would be true if its function were concerned with the conser-
vation of the proper conformation of the molecule, e.g.,
through intramolecular interactions with the aa 105 to 123
region, given the presence of a cysteine in both domains.
The observation that PC3 is phosphorylated by CDK2 sug-
gests that the effect of growth inhibition exerted by the PC3
molecule might be regulated in a cell-cycle-dependent fashion.
However, we have observed that the inhibition of colony for-
mation by the phosphorylation-defective mutant of PC3 is only
slightly lower than that of the wild-type molecule. We can also
tentatively exclude an effect of the phosphorylation by CDK2
on the stability or the intracellular localization of the PC3
protein, since mutant pSCT-PC3 S147N appears to be ex-
pressed to the same extent as the wild-type molecule, with no
apparent differences in the intracellular pattern. We cannot
exclude the phosphorylation of other sites by other kinases as
a requirement to bring an effect into evidence, but presently,
the functional role of the CDK2-dependent phosphorylation of
PC3 remains to be defined.
Physiological role of the G1 arrest by PC3. The model for
PC3 activity presented here, proposing that PC3 activity in-
duces G1 arrest by targeting pRb function through cyclin D1
down-regulation, raises questions about the functional ratio-
nale for such activity. So far, the expression of PC3/TIS21/
BTG2 has been shown to increase at the onset of neuronal
differentiation in cell lines and in vivo (9, 47), at the onset of
and during neuronal apoptosis (67), or following DNA damage
through a p53-dependent mechanism (92). Evidence has been
presented for a role of PC3/TIS21/BTG2 in the growth arrest
of the neuroblast preceding its differentiation into postmitotic
neuron (47, 48) and in cell survival after genotoxic damage
(92). The cellular condition of DNA damage is associated with
a decrease of cyclin D1 levels (79, 83, 100). In fact, it has been
shown previously that a decrease of cyclin D1 induced by
antisense cDNA accelerates DNA repair (79). In this regard, it
is known that cyclin D1 associates directly with the proliferat-
ing cell nuclear antigen (PCNA) (116), i.e., the auxiliary factor
of DNA polymerases d and e , required for DNA replication
and repair (11, 84, 104), and that a down-regulation of cyclin
D1 is necessary for PCNA relocation and DNA repair synthe-
sis (79). It is therefore interesting to hypothesize that PC3
might play a role in DNA damage through an effect on cyclin
D1 levels, in an Rb-dependent fashion. Regarding the process
of neuronal differentiation, PC3 and pRb are expressed during
development mainly in areas where embryonic cells proliferate
and eventually differentiate (47, 54). Furthermore, it has been
shown that animals ablated of the Rb gene by targeting die in
utero, displaying major defects in neuronal differentiation. In
fact, neuroblasts continue to proliferate without arrest, until
they undergo massive apoptosis (54). Very similar defects were
detected in skeletal muscle differentiation (119). It is also very
suggestive that PC3 expression occurs in vivo in the period
when dephosphorylation of pRb is observed (54), thus mirror-
ing our data in vitro. However, pRb expression continues in the
adult neuron, while PC3 is completely shut off. Shown in Fig.
14 is a working model summarizing PC3 action.
We should also consider that the above model for the action
of PC3 presents some incongruities. In fact, while PC3 expres-
sion is directly induced by p53 (92), it has been observed that
exogenous expression of p53 induces cyclin D1 levels (17, 23).
Such an increase of cyclin D1 levels by p53 has been shown to
be mediated by p21 and to be necessary for G1 arrest, possibly
as a consequence of the binding to PCNA (17, 23). Thus, a
conflict with our model appears evident in regard to the p53
action, which increases cyclin D1 levels and at the same time
induces PC3, which in turn should effect a reduction of cyclin
D1 levels. Indeed, we have observed that activation of p53 in
the mouse BALB/c cell line Val 5 containing the temperature-
sensitive mutant p53Val135, kindly provided by C. Schneider
and G. Del Sal (23), induced p21 and cyclin D1 expression as
expected but did not induce either PC3 protein or mRNA
FIG. 14. A working model of PC3 activity. PC3, by modulating cyclin D1
levels, leads to dephosphorylation of pRb and consequent growth arrest. PC3 is
normally not expressed in proliferating cells but is induced in response to diverse
growth arrest stimuli (e.g., terminal differentiation and DNA damage). The
dashed lines indicate pathways not experimentally implicated in this report.
phosph., phosphorylation; cyc, cyclin.
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(data not shown). This suggests that the induction of PC3 by
p53 is somewhat dependent on the cell system used. Further-
more, DNA damage induces PC3/BTG2 and p53 levels (92,
120; D. Guardavaccaro and F. Tirone, unpublished data) and
reduces cyclin D1 levels (79, 83, 100), but this latter effect has
also been shown to occur in the absence of p53 (100). There-
fore, this experimental evidence indicates that further studies
are necessary to assess the possibility of PC3 being a mediator
of G1 inhibition by p53.
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